BioCentury | Dec 24, 2012
Clinical News

DPK-060: Phase II data

...Sweden), including Pergamum. In 2009, Karolinska combined its portfolio companies DermaGen, Lipopeptide, Omnio Healer AB, BioCis Pharma...
BioCentury | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

...CEO. Laurantis' lead candidates target inflammatory diseases, dermatitis and bladder cancer. Terms were not disclosed. BioCis Pharma...
BioCentury | Mar 7, 2011
Company News

Pergamum, Karolinska Development dermatology, musculoskeletal news

...and DermaGen AB. In 2009, Karolinska combined its portfolio companies DermaGen, Lipopeptide, Omnio Healer AB, BioCis Pharma...
BioCentury | Sep 14, 2009
Company News

Karolinska Development dermatology, musculoskeletal news

...AB . Karolinska also transferred its minority holdings in Omnio Healer AB (Umea, Sweden) and BioCis Pharma...
...AB . Karolinska also transferred its minority holdings in Omnio Healer AB (Umea, Sweden) and BioCis Pharma...
BioCentury | Jul 13, 2009
Clinical News

ProtoCure emulsion cream: Phase IIa data

...which the company attributed to the small study size. There were no serious adverse events. BioCis Pharma...
BioCentury | Jun 1, 2009
Clinical News

ProtoCure instillation solution: Phase I started

...intravesical ProtoCure instillation solution in 22 patients with primary or recurrent non-muscle invasive bladder cancer. BioCis Pharma...
BioCentury | Mar 16, 2009
Clinical News

ProtoCure: Phase IIa started

...Phase IIa trial to evaluate topical ProtoCure for up to 4 weeks in 18 patients. BioCis Pharma...
BioCentury | Nov 10, 2008
Clinical News

ProtoCure: Phase IIa started

...BioCis began a double-blind, vehicle-controlled Phase IIa trial of topical ProtoCure in 18 patients. BioCis Pharma Ltd...
BioCentury | Mar 10, 2008
Clinical News

ProtoCure: Phase I started

...BioCis began a double-blind, placebo-controlled, Finnish Phase I trial of topical ProtoCure in healthy volunteers. BioCis Pharma...
Items per page:
1 - 9 of 9
BioCentury | Dec 24, 2012
Clinical News

DPK-060: Phase II data

...Sweden), including Pergamum. In 2009, Karolinska combined its portfolio companies DermaGen, Lipopeptide, Omnio Healer AB, BioCis Pharma...
BioCentury | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

...CEO. Laurantis' lead candidates target inflammatory diseases, dermatitis and bladder cancer. Terms were not disclosed. BioCis Pharma...
BioCentury | Mar 7, 2011
Company News

Pergamum, Karolinska Development dermatology, musculoskeletal news

...and DermaGen AB. In 2009, Karolinska combined its portfolio companies DermaGen, Lipopeptide, Omnio Healer AB, BioCis Pharma...
BioCentury | Sep 14, 2009
Company News

Karolinska Development dermatology, musculoskeletal news

...AB . Karolinska also transferred its minority holdings in Omnio Healer AB (Umea, Sweden) and BioCis Pharma...
...AB . Karolinska also transferred its minority holdings in Omnio Healer AB (Umea, Sweden) and BioCis Pharma...
BioCentury | Jul 13, 2009
Clinical News

ProtoCure emulsion cream: Phase IIa data

...which the company attributed to the small study size. There were no serious adverse events. BioCis Pharma...
BioCentury | Jun 1, 2009
Clinical News

ProtoCure instillation solution: Phase I started

...intravesical ProtoCure instillation solution in 22 patients with primary or recurrent non-muscle invasive bladder cancer. BioCis Pharma...
BioCentury | Mar 16, 2009
Clinical News

ProtoCure: Phase IIa started

...Phase IIa trial to evaluate topical ProtoCure for up to 4 weeks in 18 patients. BioCis Pharma...
BioCentury | Nov 10, 2008
Clinical News

ProtoCure: Phase IIa started

...BioCis began a double-blind, vehicle-controlled Phase IIa trial of topical ProtoCure in 18 patients. BioCis Pharma Ltd...
BioCentury | Mar 10, 2008
Clinical News

ProtoCure: Phase I started

...BioCis began a double-blind, placebo-controlled, Finnish Phase I trial of topical ProtoCure in healthy volunteers. BioCis Pharma...
Items per page:
1 - 9 of 9